Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer

Gastric Cancer

Volumn 15, Issue 2, 2012, Pages 137-143

  Shitara, Kohei ^a   Ikeda, Junko ^a   Kondo, Chihiro ^a   Takahari, Daisuke ^a   Ura, Takashi ^a   Muro, Kei ^a   Matsuo, Keitaro ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Prognostic factor; Randomized trial; Stratification

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; FUNCTIONAL STATUS; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MEDICAL ERROR; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CODING; PERITONEUM METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TUMOR LOCALIZATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STOMACH; STOMACH NEOPLASMS;

EID: 84861529047     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0083-8     Document Type: Review

References (26)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50. (Pubitemid 46655601)
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7. (Pubitemid 46631401)
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-73.
6. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-53.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
8. Kang Y, Ohtsu A, Van Cutsem E, Roman L, Nunes J, Li C, et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol. 2010;28:18s (suppl; abstr LBA4007).
9. Ohtsu A. Diverse Eastern and Western approaches to the management of gastric cancer. Gastrointest Cancer Res. 2007;1:S10-5.
10. Pozzo C, Ohashi Y, on behalf of the GASTRIC project. Metaanalyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J Clin Oncol. 2009;27:15s (suppl; abstr 4550).
11. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer. Pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395-403. (Pubitemid 41121931)
12. Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol. 2009;27:e3-4.
13. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol. 2004;34:654-9. (Pubitemid 41615277)
14. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61:301-7. (Pubitemid 350160328)
15. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, for the CONSORT group, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371: 281-83.
16. Sorbye H, Köhne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007;18: 1666-72. (Pubitemid 47506253)
17. Yamada Y, Yamamoto S, Ohtsu A, Suzuki Y, Nasu J, Yamaguchi K, et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol. 2009;27:15s (suppl; abstr 4535).
18. Bang Y, Chung H, Sawaki A, Xu J, Shen L, Lipatov O, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27:15s (suppl; abstr 4556).
19. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;27:15s (suppl; abstr 4540).
20. Takiuchi H, Fukuda H, Boku N, Shimada Y, Nasu J, Hamamoto Y, et al. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). J Clin Oncol. 2010;28:15s (suppl; abstr 4052).
21. Takashima A, Boku N, Kato K, Mizusawa J, Nakamura K, Fukuda H, et al. Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): results from combined analysis of JCOG9205 and JCOG9912. J Clin Oncol. 2010;28:15s (suppl; abstr 4061).
22. Shitara K, Ikeda J, Yokota T, Takahari D, Ura T, Muro K, et al. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs. 2011;Epub ahead of print.
23. Bajorin D. The phase III candidate: can we improve in the science of selection? J Clin Oncol. 2004;22:211-3. (Pubitemid 41095082)
24. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI, et al. Stratified randomization for clinical trials. J Clin Epidemiol. 1999;52:19-26. (Pubitemid 29064270)
25. Nam JM. Sample size determination in stratified trials to establish the equivalence of two treatments. Stat Med. 1995;14:2037-49.
26. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.